Drug Type Small molecule drug |
Synonyms 4-(5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile, Topiroric, Topiroxostat (JAN/INN) + [7] |
Target |
Mechanism XO inhibitors(Xanthine dehydrogenase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (28 Jun 2013), |
Regulation- |
Molecular FormulaC13H8N6 |
InChIKeyUBVZQGOVTLIHLH-UHFFFAOYSA-N |
CAS Registry577778-58-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09786 | Topiroxostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Gout | JP | 28 Jun 2013 | |
Gout | JP | 28 Jun 2013 | |
Gout | JP | 28 Jun 2013 | |
Hyperuricemia | JP | 28 Jun 2013 | |
Hyperuricemia | JP | 28 Jun 2013 | |
Hyperuricemia | JP | 28 Jun 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Nephropathies | Phase 2 | JP | 30 Dec 2014 | |
Diabetic Nephropathies | Phase 2 | JP | 30 Dec 2014 |
Not Applicable | Chronic Kidney Diseases serum urate levels | urinary albumin excretion | - | ysymaitgaz(wehhgmapuw) = yjpmfqasxs byunvzcmsm (pwauvyweeo ) | Positive | 21 May 2015 | ||
Placebo | ysymaitgaz(wehhgmapuw) = pglwcoqosi byunvzcmsm (pwauvyweeo ) |